Skip to Content

Novo Nordisk A/S ADR NVO

Morningstar Rating
$126.16 −2.48 (1.93%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Novo Nordisk's Diabetes and Obesity Market Dominance and Pipeline Innovation Support a Wide Moat

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 32% of the $50 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.

Price vs Fair Value

NVO is trading at a 53% premium.
Price
$128.64
Fair Value
$88.00
Uncertainty
High
1-Star Price
$518.20
5-Star Price
$52.40
Economic Moat
Thb
Capital Allocation
Jrtqcdvp

Bulls Say, Bears Say

Bulls

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

Bears

Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from U.S. pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed on category pricing since 2017.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$128.64
Day Range
$125.35127.32
52-Week Range
$75.56138.28
Bid/Ask
$124.63 / $125.70
Market Cap
$562.84 Bil
Volume/Avg
3.1 Mil / 4.9 Mil

Key Statistics

Price/Earnings (Normalized)
46.70
Price/Sales
16.82
Dividend Yield (Trailing)
1.10%
Dividend Yield (Forward)
1.10%
Total Yield
1.86%

Company Profile

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
60,000

Competitors

Valuation

Metric
NVO
SNY
LLY
Price/Earnings (Normalized)
46.7010.0487.27
Price/Book Value
35.551.5664.53
Price/Sales
16.822.3819.38
Price/Cash Flow
32.2511.6690.66
Price/Earnings
NVO
SNY
LLY

Financial Strength

Metric
NVO
SNY
LLY
Quick Ratio
0.620.830.52
Current Ratio
0.821.270.94
Interest Coverage
192.1511.0314.13
Quick Ratio
NVO
SNY
LLY

Profitability

Metric
NVO
SNY
LLY
Return on Assets (Normalized)
30.82%8.05%10.22%
Return on Equity (Normalized)
94.27%14.38%52.03%
Return on Invested Capital (Normalized)
72.84%10.85%19.27%
Return on Assets
NVO
SNY
LLY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
VRTX
Vertex Pharmaceuticals IncZgqftpvVgmmf$103.6 Bil
REGN
Regeneron Pharmaceuticals IncRnmqgktYxjmx$99.5 Bil
MRNA
Moderna IncQbymyrbYlzd$38.8 Bil
ARGX
argenx SE ADRWbmwzxjrXqcf$22.3 Bil
BNTX
BioNTech SE ADRCbmhjlbyFkw$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncKswknjvqvQbhctg$18.2 Bil
BMRN
Biomarin Pharmaceutical IncFnxrvwxhyRczyckw$17.3 Bil
RPRX
Royalty Pharma PLC Class AJxkgwltzvDnhzdk$12.5 Bil
INCY
Incyte CorpNzvmdntVfqwbn$11.6 Bil

Sponsor Center